<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font21 { font-size : 21; } .font22 { font-size : 22; } .font27 { font-size : 27; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">phenytoin </span>
   <span class="font27">CYPC </span>
   <span class="font22">MDR </span>
   <span class="font21">polymorphisms </span>
   <span class="font21">patients </span>
   <span class="font21">genotype </span>
   <span class="font19">volunteers </span>
   <span class="font18">Healthy </span>
   <span class="font18">Patients </span>
   <span class="font18">exp </span>
   <span class="font18">studies </span>
   <span class="font17">genetic </span>
   <span class="font17">polymorphism </span>
   <span class="font16">gene </span>
   <span class="font16">study </span>
   <span class="font16">serum </span>
   <span class="font15">clinical </span>
   <span class="font15">taking </span>
   <span class="font15">drug </span>
   <span class="font15">impact </span>
   <span class="font15">MENA </span>
   <span class="font15">[]. </span>
   <span class="font15">epilepsy </span>
   <span class="font15">Turkey </span>
   <span class="font15">allelic </span>
   <span class="font15">warfarin </span>
   <span class="font14">concentrations </span>
   <span class="font14">frequencies </span>
   <span class="font14">reported </span>
   <span class="font14">variants </span>
   <span class="font14">significantly </span>
   <span class="font14">Turkish </span>
   <span class="font13">CYPC* </span>
   <span class="font13">CYPC, </span>
   <span class="font13">maintenance </span>
   <span class="font13">pharmacokinetics </span>
   <span class="font13">&amp;lt; </span>
   <span class="font13">associated </span>
   <span class="font13">genotypes </span>
   <span class="font13">outcomes </span>
   <span class="font13">region </span>
   <span class="font13">resistance </span>
   <span class="font13">cytochrome </span>
   <span class="font13">included </span>
   <span class="font13">significant </span>
   <span class="font13">{border-style </span>
   <span class="font13">alleles </span>
   <span class="font13">dose </span>
   <span class="font13">Iran </span>
   <span class="font13">Iranian </span>
   <span class="font13">Saudi </span>
   <span class="font13">Yes </span>
   <span class="font13">association </span>
   <span class="font13">px;} </span>
   <span class="font13">variability </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">populations </span>
   <span class="font12">review </span>
   <span class="font12">wild-type </span>
   <span class="font12">CYPC*/* </span>
   <span class="font12">Clin </span>
   <span class="font12">Middle </span>
   <span class="font12">North </span>
   <span class="font12">antiepileptic </span>
   <span class="font12">assessed </span>
   <span class="font12">conducted </span>
   <span class="font12">results </span>
   <span class="font12">variant </span>
   <span class="font12">(ABCB) </span>
   <span class="font12">East </span>
   <span class="font12">originating </span>
   <span class="font12">*/* </span>
   <span class="font12">Egypt </span>
   <span class="font12">PHT </span>
   <span class="font12">analysis </span>
   <span class="font12">concentration </span>
   <span class="font12">data </span>
   <span class="font12">population </span>
   <span class="font12">response </span>
   <span class="font12">.), </span>
   <span class="font12">Africa </span>
   <span class="font12">drug-resistant </span>
   <span class="font12">group </span>
   <span class="font12">likely </span>
   <span class="font12">multidrug </span>
   <span class="font12">adverse </span>
   <span class="font12">different </span>
   <span class="font12">healthy </span>
   <span class="font12">identified </span>
   <span class="font12">metabolism </span>
   <span class="font12">mg/L </span>
   <span class="font12">region. </span>
   <span class="font12">seizure </span>
   <span class="font11">(.) </span>
   <span class="font11">Egyptian </span>
   <span class="font11">Pharmacol </span>
   <span class="font11">allele </span>
   <span class="font11">cancer </span>
   <span class="font11">coronary </span>
   <span class="font11">did </span>
   <span class="font11">genotypic </span>
   <span class="font11">pharmacokinetic </span>
   <span class="font11">(%) </span>
   <span class="font11">*/**/*, </span>
   <span class="font11">breast </span>
   <span class="font11">cutaneous </span>
   <span class="font11">effect </span>
   <span class="font11">enzymes </span>
   <span class="font11">frequency </span>
   <span class="font11">phenytoin-induced </span>
   <span class="font11">potential </span>
   <span class="font11">therefore, </span>
   <span class="font11">CYPC*/*, </span>
   <span class="font11">Cytochrome </span>
   <span class="font11">Drug </span>
   <span class="font11">Kerb </span>
   <span class="font11">Study </span>
   <span class="font11">VKORC </span>
   <span class="font11">[], </span>
   <span class="font11">associations </span>
   <span class="font11">clopidogrel </span>
   <span class="font11">countries </span>
   <span class="font11">plasma </span>
   <span class="font11">primary </span>
   <span class="font11">reduced </span>
   <span class="font11">severe </span>
   <span class="font11">(i.e., </span>
   <span class="font11">.). </span>
   <span class="font11">ABCB </span>
   <span class="font11">Arabia </span>
   <span class="font11">Genotypic </span>
   <span class="font11">Moreover, </span>
   <span class="font11">PCI </span>
   <span class="font11">Table </span>
   <span class="font11">acute </span>
   <span class="font11">al.The </span>
   <span class="font11">compared </span>
   <span class="font11">difference </span>
   <span class="font11">differences </span>
   <span class="font11">doses </span>
   <span class="font11">functional </span>
   <span class="font11">impacts </span>
   <span class="font11">influence </span>
   <span class="font11">lower </span>
   <span class="font11">multiple </span>
   <span class="font11">px; </span>
   <span class="font11">reactions </span>
   <span class="font11">single </span>
   <span class="font11">time </span>
   <span class="font11">toxicity </span>
   <span class="font11">{font-family </span>
   <span class="font11">(.). </span>
   <span class="font11">Accessed </span>
   <span class="font11">Biol </span>
   <span class="font11">Genotype </span>
   <span class="font11">Jordan </span>
   <span class="font11">MAF </span>
   <span class="font11">Mol </span>
   <span class="font11">[–]. </span>
   <span class="font11">al.Association </span>
   <span class="font11">dosing </span>
   <span class="font11">expression </span>
   <span class="font11">factors </span>
   <span class="font11">female </span>
   <span class="font11">font-size </span>
   <span class="font11">human </span>
   <span class="font11">inclusion </span>
   <span class="font11">mean </span>
   <span class="font11">poor </span>
   <span class="font11">quality </span>
   <span class="font11">regarding </span>
   <span class="font11">risk </span>
   <span class="font11">role </span>
   <span class="font11">sample </span>
   <span class="font11">search </span>
   <span class="font11">therapy </span>
   <span class="font11">(.–.). </span>
   <span class="font11">CYPC*, </span>
   <span class="font11">Health </span>
   <span class="font11">National </span>
   <span class="font11">Ozkaynakci </span>
   <span class="font11">References </span>
   <span class="font11">Sample </span>
   <span class="font11">al.Genetic </span>
   <span class="font11">double; </span>
   <span class="font11">familial </span>
   <span class="font11">higher </span>
   <span class="font11">however, </span>
   <span class="font11">increased </span>
   <span class="font11">investigated </span>
   <span class="font11">major </span>
   <span class="font11">participants </span>
   <span class="font11">polymorphic </span>
   <span class="font11">ratio </span>
   <span class="font11">region, </span>
   <span class="font11">regression </span>
   <span class="font11">required </span>
   <span class="font11">resistant </span>
   <span class="font11">result </span>
   <span class="font11">size </span>
   <span class="font11">subjects </span>
   <span class="font11">therapeutic </span>
   <span class="font11">trough </span>
   <span class="font11">unclear </span>
   <span class="font10">-month </span>
   <span class="font10">.–.; </span>
   <span class="font10">ACS </span>
   <span class="font10">Allelic </span>
   <span class="font10">Aynacioglu </span>
   <span class="font10">Children </span>
   <span class="font10">Ctr </span>
   <span class="font10">Diagn </span>
   <span class="font10">Ebid </span>
   <span class="font10">Feb </span>
   <span class="font10">Female </span>
   <span class="font10">Knowledge </span>
   <span class="font10">Mediterranean </span>
   <span class="font10">Pharmacol../s--- </span>
   <span class="font10">Serum </span>
   <span class="font10">Ther../s--- </span>
   <span class="font10">acenocoumarol </span>
   <span class="font10">achieve </span>
   <span class="font10">affect </span>
   <span class="font10">assess </span>
   <span class="font10">assessed, </span>
   <span class="font10">assessed. </span>
   <span class="font10">assessing </span>
   <span class="font10">assessment </span>
   <span class="font10">based </span>
   <span class="font10">baseline </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">clearly </span>
   <span class="font10">clinic </span>
   <span class="font10">collected </span>
   <span class="font10">common </span>
   <span class="font10">disease </span>
   <span class="font10">dosage </span>
   <span class="font10">drug-responsive </span>
   <span class="font10">drugs </span>
   <span class="font10">effects </span>
   <span class="font10">epileptic </span>
   <span class="font10">ethnic </span>
   <span class="font10">excluded </span>
   <span class="font10">groups </span>
   <span class="font10">guidelines </span>
   <span class="font10">haplotype </span>
   <span class="font10">haplotypes </span>
   <span class="font10">https://www.pharmgkb.org/. </span>
   <span class="font10">identify </span>
   <span class="font10">indicated </span>
   <span class="font10">limitations </span>
   <span class="font10">maximum </span>
   <span class="font10">nucleotide </span>
   <span class="font10">patient </span>
   <span class="font10">patients, </span>
   <span class="font10">populationClin </span>
   <span class="font10">possible </span>
   <span class="font10">presence </span>
   <span class="font10">protein </span>
   <span class="font10">receiving </span>
   <span class="font10">reporting </span>
   <span class="font10">responsive </span>
   <span class="font10">seizures </span>
   <span class="font10">solid; </span>
   <span class="font10">substrate </span>
   <span class="font10">suggest </span>
   <span class="font10">systematic </span>
   <span class="font10">transplant </span>
   <span class="font10">transporters </span>
   <span class="font10">using </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(MDR) </span>
   <span class="font10">(OR </span>
   <span class="font10">*/*) </span>
   <span class="font10">.PharmGKB. </span>
   <span class="font10">Alhazzani </span>
   <span class="font10">Biol../dna.. </span>
   <span class="font10">CAD </span>
   <span class="font10">Cell </span>
   <span class="font10">Data </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Future </span>
   <span class="font10">GT/A </span>
   <span class="font10">HLA-B*: </span>
   <span class="font10">Israeli </span>
   <span class="font10">Jordanian </span>
   <span class="font10">Lebanese </span>
   <span class="font10">MACE </span>
   <span class="font10">MEDLINE </span>
   <span class="font10">Med </span>
   <span class="font10">Quality </span>
   <span class="font10">Rep../s--- </span>
   <span class="font10">Results </span>
   <span class="font10">Studies </span>
   <span class="font10">UGTA.mp. </span>
   <span class="font10">absolute </span>
   <span class="font10">activity </span>
   <span class="font10">adjusted </span>
   <span class="font10">adult </span>
   <span class="font10">al.Influence </span>
   <span class="font10">alleles, </span>
   <span class="font10">and/or </span>
   <span class="font10">artery </span>
   <span class="font10">bold </span>
   <span class="font10">capacity </span>
   <span class="font10">case-control </span>
   <span class="font10">children </span>
   <span class="font10">cohort </span>
   <span class="font10">concentration, </span>
   <span class="font10">courier; </span>
   <span class="font10">criteria </span>
   <span class="font10">defined </span>
   <span class="font10">developed </span>
   <span class="font10">development </span>
   <span class="font10">efficacy </span>
   <span class="font10">eligible </span>
   <span class="font10">em; </span>
   <span class="font10">evaluate </span>
   <span class="font10">final </span>
   <span class="font10">following </span>
   <span class="font10">groups, </span>
   <span class="font10">indicate </span>
   <span class="font10">individuals </span>
   <span class="font10">interpatient </span>
   <span class="font10">investigation. </span>
   <span class="font10">level </span>
   <span class="font10">measured </span>
   <span class="font10">mg/L, </span>
   <span class="font10">number </span>
   <span class="font10">objective </span>
   <span class="font10">originated </span>
   <span class="font10">outpatients </span>
   <span class="font10">owing </span>
   <span class="font10">p-HPPH-to-phenytoin </span>
   <span class="font10">phenytoin. </span>
   <span class="font10">populationMol </span>
   <span class="font10">prevalence </span>
   <span class="font10">profile </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">range </span>
   <span class="font10">requirements </span>
   <span class="font10">research </span>
   <span class="font10">respectively. </span>
   <span class="font10">resultant </span>
   <span class="font10">secondary </span>
   <span class="font10">significance </span>
   <span class="font10">small </span>
   <span class="font10">specifically </span>
   <span class="font10">statistically </span>
   <span class="font10">syndrome, </span>
   <span class="font10">transporter </span>
   <span class="font10">used </span>
  </p>
 </body>
</html>
